Structure Therapeutics Inc. (GPCR) 10-Year Financial Performance & Capital Metrics

GPCR • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.Show more

Revenue $0
EBITDA -$157M -53.4%
Net Income -$123M -36.7%
EPS (Diluted) -2.34 +3.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -18.6% +65.0%
ROIC -23.09% +71.9%
Debt/Equity 0.00 -62.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Shares diluted 43.3% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-90.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM-61.33%

ROCE

10Y Avg-43.43%

5Y Avg-43.43%

3Y Avg-39.31%

Latest-23.89%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.77B	5.77	59.36	43.5%	9.32%		1.85%
CORTCorcept Therapeutics Incorporated	3.93B	37.36	30.37	39.94%	14.19%	16.65%	4.98%	0.01
GUTSFractyl Health, Inc. Common Stock	306.74M	2.00	-1.23	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	428.81M	1.18	-1.87	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	232.75M	2.51	-2.56			-52.45%		0.01
BIOABioAge Labs, Inc.	640.01M	17.85	-2.69		-12.81%	-27.32%		0.03
MISTMilestone Pharmaceuticals Inc.	166.93M	1.96	-2.93	-100%		-282.97%		4.17
ALTAltimmune, Inc.	422.59M	4.05	-3.02	-95.31%	-4195.75%	-45.21%		0.01

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	20.03K	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-20.03K	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-	-
Operating Expenses+	15.91M	37.7M	52.56M	102.78M	158.23M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	3.53M	8.59M	16.37M	32.67M	49.41M
SG&A % of Revenue	-	-	-	-	-
Research & Development	12.39M	29.11M	36.19M	70.1M	108.81M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-15.93M	-37.7M	-52.56M	-102.78M	-158.23M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-1.37%	-0.39%	-0.96%	-0.54%
EBITDA+	-15.91M	-37.62M	-52.28M	-102.48M	-157.24M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-1.36%	-0.39%	-0.96%	-0.53%
D&A (Non-Cash Add-back)	20.03K	72K	277K	295K	992K
EBIT	-15.77M	-37.7M	-52.56M	-102.78M	-158.23M
Net Interest Income+	168K	-122.04K	1.26M	-11.64K	36.01M
Interest Income	168.29K	122	1.26M	13.38M	36.03M
Interest Expense	0	122.16K	0	13.39M	0
Other Income/Expense	168.29K	-122K	1.26M	13.39M	36.01M
Pretax Income+	-15.77M	-37.82M	-51.3M	-89.38M	-122.22M
Pretax Margin %	-	-	-	-	-
Income Tax+	138.24K	231K	17K	236K	310K
Effective Tax Rate %	1.01%	1.06%	1%	1%	1%
Net Income+	-15.9M	-40.01M	-51.32M	-89.62M	-122.53M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1.52%	-0.28%	-0.75%	-0.37%
Net Income (Continuing)	-15.9M	-38.05M	-51.32M	-89.62M	-122.53M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.45	-1.20	-1.44	-2.43	-2.34
EPS Growth %	-	-1.67%	-0.2%	-0.69%	0.04%
EPS (Basic)	-0.45	-1.20	-1.44	-2.43	-2.34
Diluted Shares Outstanding	36.59M	36.59M	36.59M	36.73M	52.64M
Basic Shares Outstanding	36.59M	36.59M	36.59M	36.73M	52.64M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	38.42M	109.25M	93.09M	473.61M	891.21M
Cash & Short-Term Investments	37.45M	107.31M	90.84M	467.32M	883.52M
Cash Only	16.35M	105.31M	26.09M	129.79M	169.51M
Short-Term Investments	21.09M	2M	64.75M	337.53M	714.01M
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	2.25M	6.29M	7.69M
Total Non-Current Assets+	285K	1.91M	4.76M	8.41M	12.12M
Property, Plant & Equipment	277K	1.79M	1.29M	8.36M	7.01M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	8K	111K	3.46M	45K	5.11M
Total Assets+	38.7M	111.16M	97.84M	482.02M	903.33M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	1.87%	-0.12%	3.93%	0.87%
Total Current Liabilities+	3.04M	8.66M	13.01M	24.74M	36.02M
Accounts Payable	1.53M	3.48M	6.01M	4.74M	8.02M
Days Payables Outstanding	27.82K	-	-	-	-
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	819K	1.94M	3.54M	4.33M	7.29M
Current Ratio	12.64x	12.62x	7.16x	19.14x	24.74x
Quick Ratio	12.64x	12.62x	7.16x	19.14x	24.74x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	58.13M	167.23M	199.97M	4.31M	2.47M
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	133K	272K	0	4.01M	2.16M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	58M	166.96M	199.97M	298K	302K
Total Liabilities	61.17M	175.89M	212.99M	29.05M	38.49M
Total Debt+	280K	621K	260K	5.45M	3.86M
Net Debt	-16.07M	-104.68M	-25.83M	-124.34M	-165.65M
Debt / Equity	-	-	-	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-308.58x	-	-7.67x	-
Total Equity+	-22.47M	-64.73M	-115.14M	452.97M	864.84M
Equity Growth %	-	-1.88%	-0.78%	4.93%	0.91%
Book Value per Share	-0.61	-1.77	-3.15	12.33	16.43
Total Shareholders' Equity	-22.47M	-64.73M	-115.14M	452.97M	864.84M
Common Stock	1K	1K	1K	14K	17K
Retained Earnings	-22.95M	-64.74M	-116.95M	-206.57M	-329.1M
Treasury Stock	0	0	0	0	0
Accumulated OCI	-1K	0	-110K	521K	914K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.28M	-32.16M	-46.12M	-79.49M	-116.64M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-1.25%	-0.43%	-0.72%	-0.47%
Net Income	-15.88M	-38.05M	-51.32M	-89.62M	-122.53M
Depreciation & Amortization	0	72K	277K	295K	992K
Stock-Based Compensation	570K	1.49M	2.51M	8.19M	18.79M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	77K	268K	-558K	-5.32M	-16.86M
Working Capital Changes	946K	4.06M	2.97M	6.97M	2.96M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	1.02M	1.9M	2.15M	-859.25K	3.31M
Cash from Investing+	-21.15M	17.86M	-62.11M	-268.34M	-358.91M
Capital Expenditures	-19K	-1.21M	-155K	-2.17M	-1.29M
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	-231.38K	0
Cash from Financing+	25.84M	103.25M	29.01M	451.53M	515.26M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	-104K	-2.49M	-20.77M	690K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-14.3M	-33.37M	-46.27M	-81.66M	-117.93M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-1.33%	-0.39%	-0.76%	-0.44%
FCF per Share	-0.39	-0.91	-1.26	-2.22	-2.24
FCF Conversion (FCF/Net Income)	0.90x	0.80x	0.90x	0.89x	0.95x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-53.06%	-18.6%
Return on Invested Capital (ROIC)	-	-	-	-82.15%	-23.09%
Debt / Equity	-	-	-	0.01x	0.00x
Interest Coverage	-	-308.58x	-	-7.67x	-
FCF Conversion	0.90x	0.80x	0.90x	0.89x	0.95x

Frequently Asked Questions

Growth & Financials

Structure Therapeutics Inc. (GPCR) grew revenue by 0.0% over the past year. Growth has been modest.

Structure Therapeutics Inc. (GPCR) reported a net loss of $210.7M for fiscal year 2024.

Dividend & Returns

Structure Therapeutics Inc. (GPCR) has a return on equity (ROE) of -18.6%. Negative ROE indicates the company is unprofitable.

Structure Therapeutics Inc. (GPCR) had negative free cash flow of $196.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener